Coronary Heart Disease in Patients With Diabetes Part I: Recent Advances in Prevention and Noninvasive Management by Berry, Colin et al.
T
a
e
i
c
s
c
i
p
c
t
c
d
m
d
c
p
R
C
h
F
M
I
B
a
Journal of the American College of Cardiology Vol. 49, No. 6, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PSTATE-OF-THE-ART PAPERS
Coronary Heart Disease in Patients With Diabetes
Part I: Recent Advances in Prevention and Noninvasive Management
Colin Berry, MD, PHD, Jean-Claude Tardif, MD, FACC, Martial G. Bourassa, MD, FACC
Montreal, Quebec, Canada
Diabetes mellitus (DM) is a worldwide epidemic. Its prevalence is rapidly increasing in both developing and
developed countries. Coronary heart disease (CHD) is highly prevalent and is the major cause of morbidity
and mortality in diabetic patients. The purpose of this review is to assess the clinical impact of recent ad-
vances in the epidemiology, prevention, and management of CHD in diabetic patients. A systematic review
of publications in this area, referenced in MEDLINE in the past 5 years (2000 to 2005), was undertaken.
Patients with CHD and prediabetic states should undergo lifestyle modifications aimed at preventing DM.
Pharmacological prevention of DM is also promising but requires further study. In patients with CHD and
DM, routine use of aspirin and an angiotensin-converting enzyme inhibitor (ACE-I)—unless contraindicated
or not tolerated—and strict glycemic, blood pressure, and lipid control are strongly recommended. The tar-
gets for secondary prevention in these patients are relatively well defined, but the strategies to achieve
them vary and must be individualized. Intense insulin therapy might be needed for glycemic control, and
high-dose statin therapy might be needed for lipid control. For blood pressure control, ACE-Is and angioten-
sin receptor blockers are considered as first-line therapy. Noncompliance, particularly with lifestyle mea-
sures, and underprescription of evidence-based therapies remain important unsolved problems.
(J Am Coll Cardiol 2007;49:631–42) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.046i
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che population health burden of diabetes mellitus (DM)
nd diabetic coronary heart disease (CHD) remains consid-
rable. Our group previously reviewed the published reports
n this area (1); therefore, this work is restricted to publi-
ations from the years 2000 to 2005. We undertook a
ystematic Medline review with the keywords: diabetes,
oronary heart disease, epidemiology, clinical trial, morbid-
ty, mortality, myocardial infarction (MI), coronary angio-
lasty, stent, and coronary bypass surgery. In addition,
ontemporary guidelines from several national and interna-
ional Societies were consulted (2–7). The present article
onstitutes the first installment of a 2-tier review that
escribes the contemporary epidemiology, prevention, and
anagement of CHD in diabetic patients. Part II will
escribe the role and changing paradigm of coronary revas-
ularization in the management of CHD in diabetic
atients.
ecent Epidemiological Data
hanging prevalence and incidence of DM is a major public
ealth and economic problem (8). Worldwide estimates of
rom the Department of Medicine, Montreal Heart Institute and Université de
ontréal, Montreal, Quebec, Canada. Dr. Tardif is the Pfizer and Canadian
nstitutes of Health Research Chair in Atherosclerosis. Dr. Berry is supported by a
ritish Heart Foundation International Fellowship.2
Manuscript received July 11, 2006; revised manuscript received September 7, 2006,
ccepted September 11, 2006.ts prevalence are expected to rise from 2.8% (171 million
eople) in 2000 to 4.4% (366 million people) in 2030 (9).
he prevalence of DM is growing rapidly in both develop-
ng and developed countries. The countries with the largest
umber of cases in 2030 will be China, India, and the U.S.
he number of Americans with DM is projected to increase
65%, from 11 million people in 2000 to 20 million people
n 2025 (prevalence of 4.0%) (10). On the basis of an
stimated linear increase in prevalence from 4.0% in 2000 to
.2% in 2050, the number of diabetic subjects in the U.S.
opulation is projected to rise to at least 29 million people
10). Overall, the projected 18-million increase in 2050 can
e attributed to demographic changes (37%), population
rowth (27%), and increasing prevalence rates (36%) (10).
Insulin resistance often precedes the onset of DM and
lready exists in the prediabetic states. Thus, abnormal
lycoregulation is a spectrum where impaired fasting glu-
ose (IFG), impaired glucose tolerance (IGT), and obesity
mainly central or abdominal obesity) are the intermediate
tages. All 3 increase the risk to develop type 2 DM. Recent
pidemiological data estimate the prevalence of IFG and
GT to be between 8% and 12% of the adult population
11). Almost 20% of middle-aged adults and 35% of the
lder population in the U.S. have some degree of abnormal
lycoregulation (12). In the year 2000, there were more than
00 million obese adults worldwide, and industrialized
ountries showed a prevalence of obesity of approximately
0%. Currently, more than one-half of the adult population
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(13). The prevalence of obesity in
children is also dramatically in-
creasing worldwide, and this
contributes to adulthood obesity
(14). The prevalence of the met-
abolic syndrome is estimated to
be 10% to 60% (15). Although it
occurs mainly in adults, it is also
present in both childhood and
adolescence. In the U.S., it
reaches 50% in severely obese
youngsters (16).
Metabolic
Derangements
Associated With DM
Insulin resistance. Type 2 DM
is a multifactorial disease that
combines hereditary and envi-
ronmental factors. Two major
metabolic derangements charac-
terize DM: decreased insulin se-
cretion by the pancreatic beta
cells, and peripheral resistance to
he action of insulin or insulin resistance. Insulin resistance
r reduced insulin action on target tissues might not be
esponsible for DM in the absence of a deficit of insulin
ecretion (17). Insulin resistance results from environmental
actors such as detrimental lifestyle habits, with progressive
eduction of physical activity and energy expenditures and
ncreased input of dietary calories, fats, and saturated fatty
cids and from genetic or congenital susceptibility to pan-
reatic beta cell dysfunction with an inability to compensate
or greater insulin requirements. Eighty percent of patients
ith type 2 DM are either obese or overweight (18).
besity and the metabolic syndrome are linked to hyperin-
ulinemia and insulin resistance and independently predict
ardiovascular disease (CVD) and coronary atherosclerosis
19–21).
The metabolic syndrome is a common metabolic disorder
hat is characterized by increases in waist circumference,
lood pressure, and triglyceride levels combined with a
eduction in high-density lipoprotein cholesterol (HDL-C)
evels and evidence of glucose intolerance (22). Reaven
nitially proposed that insulin resistance was the main
ulprit (1), but Lemieux et al. (23) recently suggested that
isceral obesity and the hypertriglyceridemic waist pheno-
ype were its central components. When the fatty cells or
dipocytes are full, they release cytokines and adipokynes
hat generate a systemic inflammatory state, damage blood
essels, and contribute to hypertension, dyslipidemia, and
nsulin resistance (24,25). Thus the metabolic syndrome
an be seen as a disorder where central obesity leads to
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
CHD  coronary heart
disease
CVD  cardiovascular
disease
HbA1c  hemoglobin A1c
HDL-C  high-density
lipoprotein cholesterol
IFG  impaired fasting
glucose
IGT  impaired glucose
tolerance
LDL-C  low-density
lipoprotein cholesterol
NCEP ATP III  National
Cholesterol Education
Program Adult Treatment
Panel III
OGTT  oral glucose
tolerance testhronic systemic inflammation, systemic endothelial dys- eunction, and insulin resistance, the main clinical com-
onents of the syndrome (12).
yperglycemia. Despite their high incidence in type 2
M, CHD risk factors only partly account for the excessive
isk of CVD (1,25). Thus, there seems to be an association
etween hyperglycemia and CVD. Epidemiological data
uggest that there is no specific threshold for glycemia in
elation with CV risk (26). However, the role of hypergly-
emia per se in the excess CV risk is still controversial. The
KPDS (United Kingdom Prospective Diabetic Study)
howed a significant relationship, although weak, between
hronic hyperglycemia and the incidence of MI (27). In the
DIC/DCCT (Epidemiology of Diabetes Interventions
nd Complications/Diabetes Control and Complications
rial) study, the incidence of CV complications was signif-
cantly reduced in type 1 diabetic patients receiving intensive
nsulin therapy initially (28). In the DIGAMI (DIabetes
ellitus, Glucose insulin infusion in Acute Myocardial
nfarction) study, intensive insulin therapy improved CV
rognosis in diabetic after MI patients (1). Although the
IGAMI-2 study confirmed that the glucose level was a
trong predictor of mortality in these patients, it did not
upport the fact that early and continued insulin-based
herapy improved survival (29). The PROACTIVE
PROspective pioglitAzone Clinical Trial In macroVascular
vents) study evaluated pioglitazone versus placebo in the
revention of CV events in patients with type 2 DM and a
istory of CVD. Two types of results were obtained: a
ignificant 16% reduction in the composite secondary end
oint of all-cause mortality, nonfatal MI, and stroke, as
ompared with placebo; and an increased risk of heart
ailure (30). The role of glitazones in CV prevention,
lthough strongly supported by experimental and clinical
ata, must be better defined. This is being evaluated in
ngoing clinical trials (Table 1).
yslipidemia. Post hoc analyses of diabetic subpopulations
n lipid intervention trials before the year 2000 suggested
hat correction of lipoprotein abnormalities led to a decrease
n CHD (1). More recently, additional clinical trials have
eported similar results. For example, the HPS (Heart
rotection Study) demonstrated that cholesterol-lowering
herapy was beneficial for people with DM even if they did
ot already have a history of CHD or high cholesterol
oncentrations (31). Allocation to 40 mg of simvastatin
aily reduced the rate of first major CV events by about
ne-quarter in a wide range of diabetic patients. The results
rom this trial supported the use of statin therapy in diabetic
ubjects with relatively normal plasma cholesterol concen-
rations (31). Several other trials have reported results
onsistent with the HPS (32–34). More recently, the
ARDS (Collaborative Atorvastatin Diabetes Study) spe-
ifically compared atorvastatin 10 mg daily with a placebo in
ype 2 diabetic patients without symptomatic CHD who
ad relatively normal lipid concentrations (35). During a
ean follow-up of 3.9 years, atorvastatin reduced major CVvents by 37%. The ongoing ASPEN (Atorvastatin Study
Glycemic Control in Patients With Diabetes Mellitus—Published and Ongoing Randomized Trials
Table 1 Glycemic Control in Patients With Diabetes Mellitus—Published and Ongoing Randomized Trials
Trial (Ref.) Status Intervention Population Primary End Point
Enrolled
(Randomized)
Follow-Up
Period
Primary End Point
Result
DIGAMI (1) Published IGI after arrival in hospital followed by multi-dose
insulin therapy for 3 months
Treated or new DM with
acute MI
All-cause mortality 1,240 (620)
Rx: 306
Control: 314
3 months
1 yr
Control: 15.6%
Rx: 12.4% NS
Control: 26.1%
Rx: 18.6%
p  0.03
DIGAMI2 (29) Published 1. 24 h IGI followed by SC insulin-based
glucose control
2. 24 h IGI followed by standard glucose control
3. Routine metabolic management
Treated or new DM with
acute MI
All-cause mortality 1,253
1. 474
2. 473
3. 306
Median 2.1 yrs 1. 23.4%
2. 21.2%
3. 17.9% NS
DCCT/EDIC (28) Published Intensive Rx: 3 insulin injections or external
pump with dose adjustments; HbA1c goal
6.05%
Conventional Rx: no specific glucose goals
beyond those needed to prevent symptoms
Type I diabetes age
13–40 yrs
Time to first of: nonfatal MI
or stroke, CV death,
subclinical MI, angina,
or coronary
revascularization
1,441 randomized
in DCCT
1,394 followed
in EDIC
Mean 17 yrs RR (95% CI):
42% (9%–63%);
p  0.02
PROACTIVE (30) Published Oral pioglitazone 15–45 mg daily vs. placebo Type II DM HbA1c 6.5% Time to all-cause mortality,
nonfatal MI, stroke, ACS,
endovascular or surgical
intervention on the
coronary or leg arteries,
or above-ankle
amputation
5,238
Active: 2,605
Placebo: 2,633
Mean 34.5
months
Active: 514
Placebo: 572
HR (95% CI):
0.90 (0.80–1.02);
p  0.095
BARI 2D (47) Ongoing a) Revascularization by PCI or surgery vs.
aggressive medical Rx
b) Insulin sensitization vs. insulin provision
(target HbA1c 7.0% for each glycemic
control strategy)
Type II DM
Angiographic CAD
amenable to
revascularization
Evidence of ischemia or
mild angina and
50% stenosis of
1 coronary arteries
Age 25 yrs
5-yr mortality 2,368 — —
VADT (84) Ongoing Initial Rx with metformin (obese) or glimepiride
(lean), followed by rosiglitazone, followed by
insulin or other oral agents to achieve goals.
Compares standard (HbA1c 8.0%–9.0%) with
excellent control (HbA1c 6.0%)
Goal of HbA1c separation 1.5% (expected 2%)
Age 45 yrs
Type II DM with
poor control
(HbA1c 7.5%)
MI, CV mortality, stroke,
new or worsening CHF,
amputation from PVD,
surgical coronary or PVD
revascularization, and
critical limb ischemia
1,792 — —
IRIS (85) Ongoing Pioglitazone or placebo DM  age 45 yrs
History of non-embolic
ischemic stroke
Elevated FBG (insulin
resistant)
Time to stroke or MI 3,136 expected — —
PPAR study (86) Ongoing Pioglitazone or:
1) instruct weight reduction, appropriate diet,
regular exercise and/or
2) prescribe sulfonylurea agents
Age 45 yrs
DM (HbA1c 6.5%)
History of MI
1. CV mortality
2. CV hospitalization
3,000 expected — —
ACS  acute coronary syndrome; CAD  coronary artery disease; CHD  coronary heart disease; CHF  congestive heart failure; CI  confidence interval; CV  cardiovascular; DM  diabetes mellitus; FBG  fasting blood glucose; Hb  hemoglobin; HR  hazard ratio;
IGI  insulin-glucose intravenous infusion; MI  myocardial infarction; NS  not significant; PCI  percutaneous coronary intervention; PPAR  peroxisome proliferator-activated receptor; PVD  peripheral vascular disease; RR  risk reduction; Rx  treatment; SC 
subcutaneous.
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Diabetes and Coronary Heart Disease: Part I February 13, 2007:631–42or the Prevention of CHD ENdpoints) also compares
torvastatin and placebo specifically in type 2 diabetic
atients.
Diabetic dyslipidemia has a characteristic lipid profile
hat includes elevated plasma triglycerides, normal or mildly
levated low-density lipoprotein cholesterol (LDL-C),
nd reduced plasma HDL-C concentrations (1). Al-
hough hypertriglyceridemia increases the risk of CHD in
M, the effect of statin therapy for the treatment of
ypertriglyceridemia before the DALI (Diabetes Atorvasta-
in Lipid Intervention) study was uncertain (1). In the
ALI study, high-dose atorvastatin therapy reduced total
holesterol, LDL-C, and apoB to a greater extent than
ow-dose atorvastatin. Plasma triglycerides decreased and
DL-C increased to a similar extent in both groups (36). In
he DAIS (Diabetes Atherosclerosis Intervention Study),
reatment with fenofibrate reduced angiographic progres-
ion of CHD in patients with type 2 DM, good glycemic
ontrol, and mild lipoprotein abnormalities (37). However,
n the FIELD (Fenofibrate Intervention and Event Low-
ring in Diabetes) trial, although fenofibrate reduced plasma
riglycerides and increased HDL-C concentrations, it did
ot significantly decrease the incidence of CV events (38).
hus, regardless of the lipid profile, current evidence does
ot warrant replacing statins as the first choice for preven-
ion of CHD in patients with DM. The potential role of
enofibrate as part of combination therapy is the focus of the
ngoing ACCORD (Action to Control CardiOvascular
isk in Diabetes) trial.
articularities of CHD in DM
n a population-based autopsy study, coronary arteries were
xamined at 5-mm intervals with a semiquantitive grading
ystem (39). High-grade atherosclerosis was defined as
rade 3 (50% to 75%) left main stem disease or grade 4
75%) disease for other arteries. Coronary atherosclerosis
as found in 49% of diabetic and 33% of nondiabetic
ecedents. Diabetic decedents more often had MI by
utopsy, ventricular dilation, high-grade atherosclerosis, and
ultivessel disease. The global atherosclerotic burden and
revalence of multivessel disease were similar in diabetic
atients without a history of CHD and in non-diabetic
atients with a history of CHD. These findings revealed a
igh prevalence of subclinical atherosclerosis in diabetic
ubjects without a clinical history of CHD. Ledru et al. (40)
ecently compared coronary disease in consecutive diabetic
nd non-diabetic angiography referrals. Coronary disease,
bjectively evaluated with 3 severity score systems, was more
evere in diabetic than in non-diabetic patients and included
igher coronary occlusion rates. However, age, gender,
DL-C concentration, and hypertension were more pow-
rful predictors of disease severity than DM. Recent case-
ontrol studies have found that, compared with non-
iabetic patients, diabetic subjects typically have more severe
oronary disease, more extensive coronary calcifications, a figher prevalence of left main stem disease, and reduced
oronary collateral artery recruitment (41–43).
Accelerated atherosclerosis and thrombosis in patients
ith DM are mainly due to systemic inflammation, oxida-
ive stress, and systemic endothelial dysfunction (25,44,45)
ombined with coagulation and platelet function abnormal-
ties (25,46,47) and impaired fibrinolysis (47).
pidemiology of CHD in DM
he prevalence of CHD rises from 2% to 4% in the general
opulation to as high as 55% among adult diabetic patients
1). Diabetes mellitus is an independent risk factor for CVD
n both men and women. Excess risk for CVD can be found
n patients with type 1 and type 2 DM, in patients in the
rediabetic stages, and in patients with obesity and with the
etabolic syndrome (26).
ortality in diabetic patients. The overall mortality from
eart disease is twice as great in men and is 4 to 5 times
igher in women with than without DM (1). Cardiovascu-
ar disease represents over one-half of all deaths in both type
and type 2 DM (48). In addition, non-CV mortality is
reater in diabetic compared with non-diabetic subjects, and
his excess risk remains constant during long-term
ollow-up (49,50). Diabetes mellitus has been considered as
CHD risk factor equivalent. In a prospective cohort study,
he age-adjusted relative risk of death from any cause was
.3 among men with DM but without CHD, 2.2 among
en with CHD and without DM, and 4.7 among men with
oth DM and CHD (51). Patients with DM are more likely
o die after an MI than patients without DM (26,52).
orbidity in diabetic patients. Diabetes is associated with
n increased risk of morbidity in patients with CHD (51).
iabetes mellitus and obesity are predictors of MI (52).
bout one-quarter of patients who present with an acute
I have DM (12). Diabetes mellitus is a predictor of
schemic stroke and heart failure, and diabetes increases the
verall CV risk in patients with heart failure (53,54).
iabetic patients undergo invasive management less often,
nd when referred for coronary angiography, they wait
onger (55,56). In addition, quality of life is reduced in DM
atients compared with nondiabetic patients (57).
echanisms for the excess CV risk attributable to DM.
he mechanisms responsible for the increased CV mortality
nd morbidity attributable to DM are multifactorial. In
ddition to a high prevalence of conventional risk factors,
mportant contributing mechanisms include insulin resis-
ance and hyperinsulinemia, hyperglycemia, subclinical ath-
rosclerosis, congestive heart failure, acute coronary syn-
romes, and end-stage renal failure (12). The first 3 items
ave been previously discussed. Increased mortality in dia-
etic patients with left ventricular dysfunction and heart
ailure can be attributed to CHD, hypertension, left ven-
ricular hypertrophy, obesity, autonomic dysfunction, and
iabetic cardiomyopathy (12,58). Diabetes is a major risk
actor for adverse outcomes in patients who suffer from
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February 13, 2007:631–42 Diabetes and Coronary Heart Disease: Part Instable angina or MI (12,26). Autonomic dysfunction
owers the threshold for life-threatening arrhythmias and
ncreases the risk of hemodynamic instability. Coagulation
nd platelet abnormalities increase the risk of thrombosis at
he site of plaque disruption and possibly increase the risk of
einfarction after thrombolytic therapy. Finally, diabetes has
merged as the leading cause of end-stage renal disease in
he U.S., and this condition carries a 5-year survival of only
0% in patients with DM and CHD (12,59). Albuminuria
s an important prognostic marker and a potential target for
herapy in hypertensive diabetic patients with impaired
enal function (60). Recent clinical trials have shown that
oth angiotensin-converting enzyme inhibitors (ACE-Is)
nd angiotensin receptor blockers (ARBs) are nephropro-
ective in patients suffering from type 2 DM, and these
ffects are independent from those attributable to blood
ressure (BP) lowering (61–64).
rimary Prevention of DM in At-Risk Individuals
creening. The American Diabetes Association recom-
ends screening for type 2 DM in at-risk individuals (4). In
articular, individuals ages 45 years or older who have a
MI 25 kg/m2 should be assessed at 3 yearly intervals.
he screening test should include a fasting blood glucose
FBG) or a 2-h oral glucose tolerance test (OGTT) (4). A
iagnosis of DM is made if 2 consecutive FG levels are
7.0 mmol/l (126 mg/dl) or a 2-h post-load value is 11.1
mol/l (200 mg/dl) within a 3-month period. In addition,
ommunity screening programs should be targeted to at-risk
ndividuals (65).
ifestyle modification. The hypothesis that type 2 DM is
reventable is supported by recent clinical trials. At least 2
ypes of interventions have demonstrated their efficacy in
erms of primary prevention of type 2 DM: lifestyle modi-
cation by dietary measures and physical exercise aiming at
eight loss, and different pharmacological interventions.
Lifestyle modification, in patients with prediabetic states,
as been shown in 3 placebo-controlled trials to markedly
educe the risk of new-onset DM (66–68) (Table 2).
utritional therapy coordinated by dieticians had an impor-
ant role in the lifestyle intervention, and individualized
herapy is currently recommended in type 2 DM (4). Along
ith 1 earlier controlled trial of lifestyle changes for the
revention of DM in at-risk patients in China (68), the
PP (Diabetes Prevention Program) and Finnish trials
upport a strong recommendation for lifestyle intervention
n patients with IGT (Table 2).
harmacological interventions. Recent trials in patients
ith hypertension and heart failure have indirectly shown
he preventive effect of ACE-Is on DM (69–72). Similar
esults were reported with ARBs (73–76). These data must
e interpreted with caution, however, because prevention of
M was not the primary end point in any of these trials.
he effect of ACE-Is and ARBs on the progression to DM ds now being tested as a primary outcome in ongoing
andomized trials (77,78) (Table 2).
Other drugs that have also been shown to reduce the new
nset of DM in at-risk subjects (obese or prediabetic
ndividuals) include acarbose (79), bezafibrate (80), and
eroxisome proliferator-activated receptor (PPAR) gamma
nhibitors (81). In the DPP, the crude incidence of DM was
1 cases/100 person-years, 7.8 cases/100 person-years, and
.8 cases/100 person-years for the placebo, metformin, and
ifestyle-intervention groups, respectively (66). Compared
ith placebo, these interventions were also associated with
ncreased time to DM onset, reduced glycosylated hemo-
lobin (HbA1c), and reduced FG concentrations. Overall,
etformin was less effective than lifestyle intervention (Fig. 1,
able 2).
econdary Prevention and
anagement of CHD in Diabetic Patients
creening for CHD in diabetic patients. Diabetes is
ommonly considered as a CHD risk equivalent (2,6).
igh-risk diabetic patients include those with typical or
typical symptoms, those 55 years or older, those with
eripheral or carotid vascular disease, and those with 2 or
ore of the following risk factors: hyperlipidemia, hyper-
ension, smoking, family history of premature CHD,
icroalbuminuria, and progressive retinopathy (82).
creening for CHD might be indicated in younger individ-
als, with a relatively short duration of DM and few risk or
iabetic complications, because most guidelines recommend
ore aggressive management of risk factors in the presence
f CHD. Detection of CHD involves the usual diagnostic
ethods, which include exercise stress testing and, as
ndicated, myocardial perfusion scintigraphy or stress
chocardiography (82).
harmacological interventions to prevent CHD in diabetes.
he implementation of lifestyle modification, including
ietary measures and aerobic exercise aiming at long-term
eight loss, are even more critical in patients with diabetic
HD than in those with DM alone, because of the higher
isk of CV events in these patients.
NTIPLATELET THERAPY. Primary prevention therapy with
spirin is recommended in diabetic patients 40 years of
ge, with additional risk factors, and/or with diabetes 10
ears’ duration (4). Contemporary guidelines recommend
rophylactic therapy with aspirin for diabetic patients with
HD (4,46). In patients who do not tolerate or have a
ontra-indication to aspirin, clopidogrel can be used as an
lternative antiplatelet agent.
A post hoc analysis of the diabetic patients randomized in
he CAPRIE (Clopidogrel versus Aspirin in Patients at
isk of Ischemic Events) study found that clopidogrel
herapy reduced the relative risk of death, MI, stroke, or
epeat hospital stay compared with aspirin therapy (83).
owever, specific randomized trials will be needed to
etermine whether clopidogrel alone or clopidogrel plus
Prevention of Diabetes Mellitus in At-Risk Individuals—Published and Ongoing Randomized Trials
Table 2 Prevention of Diabetes Mellitus in At-Risk Individuals—Published and Ongoing Randomized Trials
Trial (Ref.) Status Intervention Population Primary End Point Randomized
Mean Follow-Up
Period Primary End Point Result
DPP (66) Published 1. Metformin 850 mg once–twice daily
2. Intensive lifestyle intervention
3. Standard lifestyle recommendations 
placebo twice daily
25 yrs; BMI 24 kg/m2 (22
in Asians)
FBG 95–125 mg/dl (5.3–
6.9 mmol/l) and 140–
199 mg/dl (7.8–11.0 mmol/l)
2 h after 75 g OGL
New onset of DM 3,234
1. 1,073
2. 1,079
3. 1,082
2.8 yrs Cases 100 patient yrs:
1. 7.8%
2. 4.8%
3. 11.0%
Incidence reduction (95% CI):
1 vs. 3: 31% (17–43)
2 vs. 3: 58% (48–66)
FINNISH trial (67) Published Rx: dietary modification, exercise
counseling and supervised
exercise programs
Usual care
40–64 yrs
Overweight and IGT*
New onset of DM 522
Rx: 265
Placebo: 257
3.2 yrs Cumulative incidence (95% CI) of
DM at 4 yrs
Intervention: 11% (6%–15%)
Control: 23% (17%–29%)
Risk reduction 0.4 (0.3–0.7);
p  0.001
CHINESE trial (68) Published Lifestyle intervention
1. Control
2. Diet
3. Exercise
4. Diet  exercise
IGT
IR based on fasting insulin, and
insulin sensitivity based on
fasting glucose concentration
New onset of DM 284
1. 62
2. 81
3. 73
4. 68
6 yrs 1. 42/62 (67.4%)
2. 36/81 (44.4%)†
3. 38/73 (52.1%)
4. 26/68 (38.2%)†
LIFE (73) Published Losartan 50–100 mg daily
Atenolol 50–100 mg daily
Age 55–80 yrs
Hypertension (SBP 160–
200 mm Hg; DBP 95–
115 mm Hg)
LVH on ECG
MI/stroke/CV death
Incidence of DM was a
predefined outcome
9,193 (13% DM)
Losartan: 4,605 (12.7%
DM)
Atenolol: 4,588 (13.3%
DM)
4.8 yrs Losartan: 508 (11%)
Atenolol: 588 (13%)
HR (95% CI): 0.87 (0.77–0.98);
p  0.021
Incidence of DM:
Losartan: 241 (6%)
Atenolol: 319 (8%)
HR (95% CI): 0.75 (0.63–0.88);
p  0.001
Acarbose (79) Published Acarbose 100 mg daily
Placebo
Non-diabetic
IGT, diagnosed with an OGTT
New DM Acarbose: 714
Placebo: 715
3.3 yrs Acarbose: 32%
Placebo: 42%
HR (95% CI): 0.75 (0.63–0.90);
p  0.0015
Bezafibrate (80) Published Bezafibrate 400 mg daily
Placebo
Non-diabetic
Obese (BMI 30 kg/m2)
Age 42–74 yrs
New DM 339
15% with IFG
6.3 yrs Bezafibrate: 42 (27%)
Placebo: 56 (37%)
p  0.01
HR (95% CI): 0.59 (0.39–0.91)
PPAR inhibitors (81) Published 1. Troglitazone
2. Placebo
3. Metformin
4. Lifestyle
Age 25 yrs
IGT
BMI 24 kg/m2
(22 kg/m2 in Native
Americans)
New DM 1. 585
2. 582
3. 587
4. 589
Mean 0.9 yrs of
troglitazone
therapy
Cases 100 patient-yrs
1. 3.0
2. 12.0
3. 6.7
4. 5.1
p  0.001, overall
1 vs. 2: p  0.01
1 vs. 3: p  0.02
DREAM (77) Ongoing 1. ACE-I (ramipril 15 mg daily)/placebo
2. Thiazolidinedione (rosiglitazone 8 mg
daily)/placebo
3. Combination
4. Placebo/placebo
Age 30 yrs
No diabetes
IFG or IGT or
IFG  IGT
New-onset type 2 DM or
all-cause mortality
5,269
IGT: 1,835 (35%)
IFG: 739 (14%)
IGT  IFG: 2,692 (51%)
— —
Continued on next page
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February 13, 2007:631–42 Diabetes and Coronary Heart Disease: Part Ispirin is superior to aspirin alone in the prevention of
ardiovascular events in diabetic patients with established
VD.
PTIMIZATION OF GLYCEMIC CONTROL. The goal of anti-
iabetic drug therapy is to ensure optimal glycemic control
HbA1c 7% for all patients and, for the individual patient,
n HbA1c as close to normal [6%] as possible) with
inimization of diabetes-related complications (4,6). There
s no specific threshold for glycemia in relation to CV risk.
hus, optimal glycemic control must be a clear objective in
iabetic patients, not only for prevention of microvascular
ut also of macrovascular events (1).
Multiple pharmacological interventions are often re-
uired, and there is still uncertainty on the best strategy to
chieve glycemic control in diabetic patients with CHD.
ntensive insulin therapy was effective in the prevention of CV
vents in the DIGAMI and EDIC/DCCT trials (Fig. 2) but
ot in the DIGAMI-2 trial. The PROACTIVE study has
hown that pioglitazone also seems to be beneficial but
hould be given carefully to patients with CHD to avoid
entricular dysfunction or heart failure. Finally, it is not
lear yet whether insulin-providing drugs such as insulin
nd sulfonylureas are more effective in the secondary pre-
ention of CVD than insulin-sensitizers such as metformin
nd the glitazones. These questions are being examined in
ngoing randomized trials (47,84–86) (Table 1).
NTIHYPERTENSIVE THERAPY. The current antihyperten-
ion treatment targets are 130/80 mm Hg in diabetic
atients (120/80 mm Hg after MI) (4,5). In the UKPDS
Figure 1 Cumulative Incidence of
Diabetes According to Study Group
The incidence of diabetes differed significantly among the 3 groups (p  0.001).
Compared with placebo, the lifestyle intervention reduced the incidence of diabe-
tes during follow-up by 58% (95% confidence interval [CI] 48% to 66%) and
metformin reduced it by 31% (95% CI 17% to 43%). The incidence of diabetes
was 39% lower (95% CI 24% to 51%) in the former than in the latter group.
Reproduced from The Diabetes Prevention Program Research Group (66) with
permission.BP-lowering substudy, intensive therapy was associatedCo T N *Im 0.0
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uc
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Diabetes and Coronary Heart Disease: Part I February 13, 2007:631–42ith reduced risks of stroke and MI (87). Greater risk
eduction was achieved with lower BP levels, and there was
o threshold for risk reduction (88). The evidence for drug
fficacy in reducing CV events in high-risk patients with
M is largely derived from subgroup analyses of recent
rials (71,89). In the ASCOT (Anglo-Scandinavian Cardiac
utcomes Trial), the benefits of the amlodipine-based
egimen (with or without perindopril) versus the atenolol-
ased regimen on rates of nonfatal MI and fatal CHD were
Figure 2 Cumulative Incidence of Cardiovascular Outcomes
Cumulative incidence of the first of any of the predefined cardiovascular disease (
CVD (B). Compared with conventional treatment, intensive diabetic treatment redu
to 63%; p  0.02) (A) and reduced the risk of the first occurrence of nonfatal MI,
from Nathan et al. (28) with permission.imilar for hypertensive patients with or without DM (89). sn the diabetic patients randomized in the MICRO-HOPE
Microalbuminuria, Cardiovascular, and Renal Outcomes-
eart Outcomes Prevention Evaluation) substudy, ramipril
educed the primary composite end point of MI, stroke, or
V death (61). Diabetic patients derived similar risk reduc-
ions with perindopril in the EUROPA (EURopean trial
n reduction of cardiac events with Perindopril in stable
oronary Artery disease) (90). In the LIFE (Losartan
ntervention For Endpoints) study reduction in hyperten-
utcomes (A) and of the first occurrence of nonfatal MI, stroke, or death from
e risk of any predefined CVD outcome by 42% (95% confidence interval [CI] 9%
, or death from CVD by 57% (95% CI 12% to 79%; p  0.02) (B). ReproducedCVD) o
ced th
strokeion study, the primary composite end point of CV death,
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February 13, 2007:631–42 Diabetes and Coronary Heart Disease: Part Itroke, or MI occurred less often in patients assigned to
osartan than in those assigned to atenolol. Thus, compared
ith a beta-blocker–based regimen, losartan therapy con-
erred consistent CV risk reduction in hypertensive diabetic
atients (91). Two ongoing ARB randomized trials assess-
ng CV prevention trials will include diabetic patients (92).
Current clinical guidelines recommend primary preven-
ion measures with ACE-I therapy in diabetic patients with
other CHD risk factor and secondary prevention with
hese drugs in diabetic patients with CHD (4,6). Recog-
izing that diabetic patients will usually need 3 or 4
ntihypertensive drugs to lower BP to the recommended
evel, ACE-Is and ARBs (along with long-acting calcium
hannel blockers) are recommended as first-line therapy
4,6). Cardioselective beta-blockers and thiazide diuretic
gents should be viewed as second-line anti-hypertensive
herapy in DM.
IPID-LOWERING THERAPY. Lipid lowering therapy is rec-
mmended for diabetic patients40 years of age or subjects
40 years of age with additional risk factors (4). The
urrent lipid target ranges are LDL-C 100 mg/dl or a
eduction in LDL-C by 30% to 40%, triglycerides 150
g/dl, and HDL-C40 mg/dl (4). In women, an HDL-C
oal of 10 mg/dl higher (50 mg/dl) might be considered.
he National Cholesterol Education Program Adult Treat-
ent Panel III (NCEP ATP III) guidelines recommend
ower LDL-C targets for patients suffering from both DM
nd CHD than for those suffering from DM alone (3). On
he basis of the HPS and other trials (26,93,94), it is
easonable to target a LDL-C of 70 mg/dl for high-risk
ubjects such as diabetic patients (3).
There is a log-linear relationship between LDL-C con-
entration and relative risk of CHD. Recent trials have
uggested that cholesterol-lowering therapy is beneficial for
atients with DM even in the absence of a history of CHD
r high cholesterol, suggesting that statin therapy should be
nitiated in DM regardless of LDL-C level (31–34,95).
hould high-risk patients have concomitant hypertriglycer-
demia or low HDL-C, it might be appropriate to add a
brate or nicotinic acid (3,95). Combination therapy with
ipid-modifying agents has not, however, been fully evalu-
ted in CVD outcomes studies, and this approach has not
et achieved an expert consensus (4).
IABETIC PATIENTS WITH UNSTABLE CAD. The established
eneficial effects of reperfusion therapy, both with primary
ercutaneous coronary intervention and fibrinolytic therapy,
nd secondary post-reperfusion prevention with antiplatelet
gents, beta-blockers, ACE-Is, and ARBs are discussed
lsewhere.
oncompliance and
nderprescription of Medication
n the DPP trial, only 50% of the lifestyle intervention
roup achieved the goal of 7% weight reduction, and 74% caintained at least 150 min/week of moderately intense
hysical activity (66).
In the NHANES (National Health and Nutrition Survey)
999 to 2000, only 37% of participants achieved the target goal
f HbA1c level 7.0% and another 37% were above the
ecommended “take action” HbA1c level of 8.0%. These
ercentages did not change significantly from the
HANES III (1988 to 1994) (96 –98). Among the
HANES III participants ages 65 years, a target HbA1c
oncentration of 7% was achieved by 71%, 44%, and 2%
f persons using no drug therapy, oral hypoglycemic agents,
nd insulin, respectively. In the NHANES 1999 to 2000,
nly 36% of patients achieved the BP target of 130/80
m Hg, and 40% had hypertensive levels (140 or 90
m Hg) despite therapy. Over one-half of the participants
n the NHANES 1999 to 2000 had cholesterol levels 200
g/dl (52% vs. 66% in the NHANES III). In the LTAP
Lipid Treatment Assessment Project), only 41% of diabetic
atients and 38% of nondiabetic patients attained the
CEP ATP III LDL-C guidelines (99).
Quite surprisingly, overall, only 7% of adults with DM in
he NHANES 1999 to 2000 attained recommended goals
f HbA1c 7%, BP 130/80 mm Hg, and cholesterol
200 mg/dl (98). Multiple sociodemographic factors might
xplain the low rate of treatment target achievement (100).
n addition to noncompliance, underprescription of
vidence-based preventive therapies is also a major issue
54,100). Thus, our efforts to jugulate the current epidemic
f DM and its CV consequences must include, as a very
igh priority, improved compliance to lifestyle measures and
rug therapy through patient and community counseling as
ell as sensibilization of the medical profession to the
mportance of primary and secondary CV prevention
hrough appropriate long-term prescription of evidence-
ased therapies.
onclusions
he global incidence and prevalence of DM is rapidly
ncreasing in both developed and developing countries.
HD in diabetic individuals represents a major worldwide
ublic health problem. Obesity, IFG, IGT, and DM form
continuous spectrum of risk of CVD. Glucose intolerance
nd the associated traditional risk factors for CVD, such as
yslipidemia and hypertension, might be present for many
ears before the diagnosis of DM. In patients with CHD
nd the prediabetic states, primary prevention of DM is now
easible and effective. In particular, lifestyle measures are
ecommended, and emerging evidence supports the role for
herapeutic prevention of type 2 DM. Because of the
pidemic proportions of DM worldwide, prevention of DM
nd prediabetic states might well be the most effective
trategy to prevent serious CV events. Morbidity and
ortality from CVD in diabetic patients with CHD are
apidly increasing. Screening for at-risk subjects can be a
ost-effective intervention. Reduction of the increased risk
o
m
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ultifactorial approach. The data currently available suggest
hat this can be achieved by intensive glycemic control and
ggressive treatment of other CV risk factors, such as
yslipidemia, hypertension, and smoking. Noncompliance,
articularly with lifestyle measures, and underprescription of
vidence-based therapies, however, remain major unsolved
roblems.
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